Murray Stahl's PFE Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 70,826 shares of Pfizer Inc. (PFE) worth $1.8 M, representing 0.02% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Murray Stahl has maintained a long-term strategic position in PFE, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2024, adding 36,370 shares. Largest reduction occurred in Q3 2025, reducing 32,357 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Pfizer (PFE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pfizer (PFE) Trades by Murray Stahl
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +58,881 | Add 0.00% | 58,880 | $28.01 |
| Q3 2013 | -215 | Reduce 0.37% | 58,665 | $28.72 |
| Q4 2013 | +2,940 | Add 5.01% | 61,605 | $30.63 |
| Q1 2014 | +1,250 | Add 2.03% | 62,855 | $32.12 |
| Q2 2014 | +106 | Add 0.17% | 62,961 | $29.67 |
| Q3 2014 | +67 | Add 0.11% | 63,028 | $29.57 |
| Q4 2014 | +1,027 | Add 1.63% | 64,055 | $31.15 |
| Q1 2015 | -3,309 | Reduce 5.17% | 60,746 | $34.78 |
| Q2 2015 | +2,030 | Add 3.34% | 62,776 | $33.52 |
| Q3 2015 | +2,965 | Add 4.72% | 65,741 | $31.41 |
| Q4 2015 | +200 | Add 0.30% | 65,941 | $32.29 |
| Q1 2016 | +2,531 | Add 3.84% | 68,472 | $29.63 |
| Q2 2016 | -217 | Reduce 0.32% | 68,255 | $35.22 |
| Q3 2016 | -2,373 | Reduce 3.48% | 65,882 | $33.86 |
| Q4 2016 | +3,518 | Add 5.34% | 69,400 | $32.48 |
| Q1 2017 | +682 | Add 0.98% | 70,082 | $34.20 |
| Q2 2017 | +3,894 | Add 5.56% | 73,976 | $33.59 |
| Q3 2017 | +980 | Add 1.32% | 74,956 | $35.70 |
| Q1 2018 | -1,589 | Reduce 2.12% | 73,367 | $35.49 |
| Q2 2018 | -3,354 | Reduce 4.57% | 70,013 | $36.28 |
| Q3 2018 | -4,050 | Reduce 5.78% | 65,963 | $44.07 |
| Q4 2018 | +646 | Add 0.98% | 66,609 | $43.64 |
| Q1 2019 | +66,510 | Add 0.00% | 66,509 | $42.48 |
| Q2 2019 | -1,138 | Reduce 1.71% | 65,371 | $43.32 |
| Q3 2019 | -3,297 | Reduce 5.04% | 62,074 | $35.92 |
| Q4 2019 | +1,958 | Add 3.15% | 64,032 | $39.18 |
| Q1 2020 | +1,193 | Add 1.86% | 65,225 | $32.64 |
| Q2 2020 | -3,743 | Reduce 5.74% | 61,482 | $32.69 |
| Q3 2020 | +1,575 | Add 2.56% | 63,057 | $36.70 |
| Q4 2020 | -7,625 | Reduce 12.09% | 55,432 | $36.80 |
| Q1 2021 | +2,253 | Add 4.06% | 57,685 | $36.23 |
| Q2 2021 | -3,268 | Reduce 5.67% | 54,417 | $39.16 |
| Q3 2021 | -1,100 | Reduce 2.02% | 53,317 | $43.01 |
| Q4 2021 | +189 | Add 0.35% | 53,506 | $59.06 |
| Q2 2022 | -1,940 | Reduce 3.63% | 51,566 | $52.44 |
| Q3 2022 | -654 | Reduce 1.27% | 50,912 | $43.76 |
| Q1 2023 | -2,550 | Reduce 5.01% | 48,362 | $40.80 |
| Q2 2023 | +209 | Add 0.43% | 48,571 | $36.68 |
| Q3 2023 | +1,850 | Add 3.81% | 50,421 | $33.17 |
| Q4 2023 | -255 | Reduce 0.51% | 50,166 | $28.79 |
| Q1 2024 | +6,979 | Add 13.91% | 57,145 | $27.75 |
| Q2 2024 | +300 | Add 0.52% | 57,445 | $27.98 |
| Q3 2024 | +36,370 | Add 63.31% | 93,815 | $28.94 |
| Q4 2024 | +6,888 | Add 7.34% | 100,703 | $26.53 |
| Q1 2025 | -677 | Reduce 0.67% | 100,026 | $25.34 |
| Q2 2025 | +3,157 | Add 3.16% | 103,183 | $24.24 |
| Q3 2025 | -32,357 | Reduce 31.36% | 70,826 | $25.48 |
Murray Stahl's Pfizer Investment FAQs
Murray Stahl first purchased Pfizer Inc. (PFE) in Q2 2013, acquiring 58,880 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Pfizer Inc. (PFE) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl's largest addition to Pfizer Inc. (PFE) was in Q1 2019, adding 66,509 shares worth $2.82 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 70,826 shares of Pfizer Inc. (PFE), valued at approximately $1.8 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Pfizer Inc. (PFE) represents approximately 0.02% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl's peak holding in Pfizer Inc. (PFE) was 103,183 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.